IGC-1C / IGC Pharma - LARVOL DELTA

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease (ACCESS Newswire) - "IGC-1C demonstrated a strong binding affinity to tau, exhibiting a dissociation constant with tau of (Kd) 3.95 ± 0.32 μM. This low micromolar-range affinity is a positive signal in drug development, reinforcing IGC-1C's efficacy in modulating the tau protein crucial for neurofibrillary tangle formation."

Preclinical • Alzheimer's Disease

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease (Businesswire) - "IGC Pharma...announced preclinical research demonstrating the therapeutic potential of IGC-1C, a novel small-molecule modulator. The findings show that IGC-1C targets tau protein phase separation, presenting new opportunities for addressing multiple pathways in neurodegenerative disease....Preclinical investigations indicate that IGC-1C exhibits a dissociation constant (Kd) of 3.95 ± 0.32 μM with tau, demonstrating a robust binding affinity that supports its potential as a therapeutic agent. The Kd value reflects the strength of the interaction between IGC-1C and tau, and this high affinity reinforces IGC-1C's efficacy in modulating tau protein, which is involved in the formation of neurofibrillary tangles, a key hallmark of Alzheimer's disease."

Preclinical • Alzheimer's Disease • CNS Disorders